Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost-utility analysis.

ABSTRACT:

Background and objectives

Foetal and neonatal alloimmune thrombocytopenia (FNAIT) results from maternal platelet-directed antibodies and can result in severe intracranial haemorrhage (ICH) in foetuses and newborns. Screening for human platelet antigen-1a (HPA-1a)-directed antibodies during pregnancy could allow timely intervention with antenatal treatment and prevent ICH. We assessed the cost effectiveness of HPA-1a typing and anti-HPA-1a-screening as part of the prenatal screening programme.

Materials and methods

Different HPA-1a screening scenarios were tested in a decision analysis model and assessed for diagnostic, treatment, intervention and lifetime costs and prevention effects compared to the current situation without screening in the Netherlands. Model parameters wer

SUBMITTER: de Vos TW 

PROVIDER: S-EPMC11839253 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature